Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Leases (2019 - 2025)

Ptc Therapeutics (PTCT) has 7 years of Current Leases data on record, last reported at $12.5 million in Q4 2025.

  • For Q4 2025, Current Leases rose 316.13% year-over-year to $12.5 million; the TTM value through Dec 2025 reached $12.5 million, up 316.13%, while the annual FY2025 figure was $12.5 million, 316.13% up from the prior year.
  • Current Leases reached $12.5 million in Q4 2025 per PTCT's latest filing, up from $2.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $14.6 million in Q1 2024 and bottomed at $1.8 million in Q1 2022.
  • Average Current Leases over 5 years is $6.0 million, with a median of $3.0 million recorded in 2021.
  • The widest YoY moves for Current Leases: up 684.71% in 2024, down 76.93% in 2024.
  • A 5-year view of Current Leases shows it stood at $3.0 million in 2021, then surged by 212.33% to $9.4 million in 2022, then soared by 38.76% to $13.0 million in 2023, then crashed by 76.93% to $3.0 million in 2024, then surged by 316.13% to $12.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $12.5 million in Q4 2025, $2.7 million in Q3 2025, and $5.4 million in Q2 2025.